Dumont & Blake Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$458K Sell
7,546
-16
-0.2% -$933 0.11% 143
2025
Q4
$408K Buy
7,562
+52
+0.7% +$2.5K 0.1% 147
2025
Q3
$339K Sell
7,510
-1,119
-13% -$52.3K 0.08% 158
2025
Q2
$399K Sell
8,629
-203
-2% -$9.96K 0.1% 150
2025
Q1
$539K Sell
8,832
-8
-0.1% -$466 0.15% 131
2024
Q4
$500K Sell
8,840
-102
-1% -$5.7K 0.13% 135
2024
Q3
$463K Sell
8,942
-1,222
-12% -$57.3K 0.12% 141
2024
Q2
$422K Buy
10,164
+1,005
+11% +$45K 0.06% 182
2024
Q1
$497K Sell
9,159
-451
-5% -$23K 0.14% 136
2023
Q4
$493K Sell
9,610
-167
-2% -$8.77K 0.15% 131
2023
Q3
$567K Sell
9,777
-14,352
-59% -$879K 0.19% 119
2023
Q2
$1.54M Sell
24,129
-76
-0.3% -$5.1K 0.5% 53
2023
Q1
$1.68M Sell
24,205
-118
-0.5% -$8.32K 0.57% 47
2022
Q4
$1.75M Sell
24,323
-79
-0.3% -$5.96K 0.62% 45
2022
Q3
$1.73M Sell
24,402
-247
-1% -$17.9K 0.65% 40
2022
Q2
$1.9M Sell
24,649
-934
-4% -$71.1K 0.62% 45
2022
Q1
$1.87M Sell
25,583
-368
-1% -$24.7K 0.51% 51
2021
Q4
$1.62M Sell
25,951
-126
-0.5% -$7.39K 0.42% 63
2021
Q3
$1.54M Buy
26,077
+70
+0.3% +$4.61K 0.44% 65
2021
Q2
$1.74M Buy
26,007
+114
+0.4% +$7.43K 0.49% 59
2021
Q1
$1.64M Buy
25,893
+178
+0.7% +$11.1K 0.5% 59
2020
Q4
$1.59M Sell
25,715
-100
-0.4% -$6.15K 0.55% 48
2020
Q3
$1.56M Sell
25,815
-67
-0.3% -$4.03K 0.59% 49
2020
Q2
$1.52M Sell
25,882
-459
-2% -$27.5K 0.64% 46
2020
Q1
$1.47M Buy
26,341
+333
+1% +$20.4K 0.75% 41
2019
Q4
$1.67M Buy
26,008
+483
+2% +$27.7K 0.66% 44
2019
Q3
$1.29M Sell
25,525
-141
-0.5% -$6.63K 0.54% 52
2019
Q2
$1.16M Buy
25,666
+2,886
+13% +$134K 0.48% 61
2019
Q1
$1.09M Buy
22,780
+1,051
+5% +$52.4K 0.46% 65
2018
Q4
$1.13M Sell
21,729
-2,136
-9% -$115K 0.53% 57
2018
Q3
$1.48M Buy
23,865
+705
+3% +$41.8K 0.58% 49
2018
Q2
$1.28M Buy
23,160
+250
+1% +$13.5K 0.54% 58
2018
Q1
$1.45M Buy
22,910
+1,580
+7% +$102K 0.62% 44
2017
Q4
$1.31M Sell
21,330
-1,644
-7% -$103K 0.53% 64
2017
Q3
$1.47M Sell
22,974
-276
-1% -$16.1K 0.63% 47
2017
Q2
$1.3M Sell
23,250
-120
-0.5% -$6.53K 0.57% 52
2017
Q1
$1.27M Buy
23,370
+8,000
+52% +$439K 0.57% 55
2016
Q4
$899K Buy
15,370
+25
+0.2% +$1.37K 0.42% 85
2016
Q3
$828K Buy
15,345
+5,235
+52% +$336K 0.41% 91
2016
Q2
$744K Sell
10,110
-150
-1% -$10.6K 0.37% 95
2016
Q1
$655K Sell
10,260
-50
-0.5% -$3.15K 0.34% 99
2015
Q4
$710K Buy
10,310
+3,310
+47% +$219K 0.36% 97
2015
Q3
$414K Sell
7,000
-3,310
-32% -$210K 0.22% 121
2015
Q2
$686K Hold
10,310
0.34% 107
2015
Q1
$664K Buy
10,310
+3,310
+47% +$207K 0.32% 109
2014
Q4
$413K Hold
7,000
0.2% 121
2014
Q3
$358K Sell
7,000
-7,430
-51% -$371K 0.18% 126
2014
Q2
$700K Hold
14,430
0.35% 105
2014
Q1
$750K Buy
14,430
+100
+0.7% +$5.32K 0.39% 100
2013
Q4
$762K Buy
14,330
+1,890
+15% +$96.3K 0.39% 102
2013
Q3
$576K Hold
12,440
0.27% 118
2013
Q2
$556K Buy
+12,440
New +$540K 0.33% 98

Other funds holding BMY

Dumont & Blake Investment Advisors's BMY Position: Q1 2026 in Review

Dumont & Blake Investment Advisors reduced its Bristol-Myers Squibb (BMY) stake by 0.21% in Q1 2026, selling an estimated $933 and leaving 7,546 shares worth $458K. The position accounts for 0.11% of the portfolio, ranked #143.

Dumont & Blake Investment Advisors first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.9M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Dumont & Blake Investment Advisors held 7,546 shares of Bristol-Myers Squibb worth $458K as of Q1 2026.
  • Dumont & Blake Investment Advisors sold 16 Bristol-Myers Squibb shares in Q1 2026, an estimated $933.
  • Bristol-Myers Squibb made up 0.11% of Dumont & Blake Investment Advisors's portfolio in Q1 2026, its #143 holding.
  • Dumont & Blake Investment Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Dumont & Blake Investment Advisors's Bristol-Myers Squibb position peaked at $1.9M in Q2 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Dumont & Blake Investment Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.